Occurrence and biological properties of sphingolipids - A review

Current Nutrition and Food Science

Volumn 3, Issue 2, 2007, Pages 161-173

  Wehrmüller, Karin ^a  

^a AGROSCOPE LIEBEFELD POSIEUX RESEARCH STATION ALP   (Switzerland)

Author keywords

Biological activity; Cancer; Cholesterol; Human nutrition; Sphingolipids; Sphingomyelin

Indexed keywords

CERAMIDE; CERAMIDE 1 PHOSPHATE; CERAMIDE PHOSPHOETHANOLAMINE; CEREBROSIDE; CHOLESTEROL; GANGLIOSIDE; GANGLIOSIDE GM1; GLYCOSPHINGOLIPID; LIPID; PHOSPHOLIPID; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SULFATIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; BACTERIAL METABOLISM; CANCER; CANCER INHIBITION; CEREBROVASCULAR ACCIDENT; CHEMICAL STRUCTURE; CHILD NUTRITION; CHOLESTEROL DIET; COLON CARCINOMA; DEGENERATIVE DISEASE; DIET THERAPY; DIETARY INTAKE; DIGESTION; FAT INTAKE; FOOD COMPOSITION; HUMAN; INFANT DISEASE; INFECTION; INTESTINE CELL; LIPID ABSORPTION; LIPID COMPOSITION; LIPID DEGRADATION; LIPID TRANSPORT; LIPOGENESIS; MYCOBACTERIUM TUBERCULOSIS; NERVE FUNCTION; NONHUMAN; PATHOGENESIS; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; REVIEW; SPINAL CORD INJURY; TISSUE DISTRIBUTION; TUBERCULOSIS;

GLYCINE MAX; MUS;

EID: 34248651297     PISSN: 15734013     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340107780598618     Document Type: Review

References (113)

1. Tudichum JLW. The chemical constitution of the brain. London, Bailliere, Tindall & Cox, 1884.
2. Rombaut R, Van Camp J, Dewettinck K. Phospho- and sphingolipid distribution during processing of milk, butter and whey. Int J Food Sci Technol 2006; 41: 435-443.
3. Merrill AH, Schmelz EM, Dillehay DL, et al. Sphingolipids - The enigmatic lipid class: biochemistry, physiology, and pathophysiology. Toxicol Appl Pharmacol 1997; 142: 208-225.
4. Huwiler A, Kolter T, Pfeilschifter J, Sandhoff K. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta 2000; 1485(2-3): 63-99.
5. Kolter T, Sandhoff K. Sphingolipids - Their metabolic pathways and the pathobiochemistry of neurodegenerative diseases. Angew Chem Int Ed 1999; 38(11): 1532-1568.
6. Futerman AH. LASS genes: mammalian ceramide synthases. Chem Phys Lipids 2006; 143(1-2): 51.
7. Sandhoff K, Kolter T. Biosynthesis and degradation of mammalian glycosphingolipids. Philos Trans R Soc Lond B Biol Sci 2003; 358(1433): 847-861.
8. Augé N, Nègre-Salvayre A, Salvayre R, Levade T. Sphingomyelin metabolites in vascular cell signaling and atherogenesis. Prog Lipid Res 2000; 39(3): 207-229.
9. Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 2004; 206(2): 169-180.
10. Spiegel S, Merrill AH. Sphingolipid metabolism and cell growth regulation. FASEB J 1996; 10(12): 1388-1397.
11. Huitema K, van den Dikkenberg J, Brouwers J, Holthuis J. Identifikation of a family of animal sphingomyelin synthases. EMBO J 2004; 23(1): 33-44.
12. Nilsson A. Metabolism of sphingomyelin in intestinal tract of rat. Biochim Biophys Acta 1968; 164(3): 575-584.
13. Nilsson A, Duan RD. Alkaline sphingomyelinases and ceramidases of the gastrointestinal tract. Chem Phys Lipids 1999; 102(1-2): 97-105.
14. Nyberg L, Nilsson A, Lundgren P, Duan RD. Localization and capacity of sphingomyelin digestion in the rat intestinal tract. J Nutr Biochem 1997; 8(3): 112-118.
15. Duan RD, Nyberg L, Nilsson A. Alkaline sphingomyelinase activity in rat gastrointestinal-tract - Distribution and characteristics. Biochim Biophys Acta 1995; 1259(1): 49-55.
16. Parodi PW. Milk fat in human nutrition. Austr J Dairy Technol 2004; 59(1): 3-59.
17. Duan RD, Hertervig E, Nyberg L, et al. Distribution of alkaline sphingomyelinase activity in human beings and animals - Tissue and species differences. Dig Dis Sci 1996; 41(9): 1801-1806.
18. Liu JJ, Nilsson A, Duan RD. Effects of phospholipids on sphingomyelin hydrolysis induced by intestinal alkaline sphingomyelinase: An in vitro study. J Nutir Biochem 2000; 11(4): 192-197.
19. Ozkara RA, Recent advances in the biochemistry and genetics of sphingolipidoses. Brain Dev 2004; 26(8): 497-505.
20. Sandhoff K, Kolter T. Topology of glycosphingolipid degradation. Trends Cell Biol 1996; 6(3): 98.103.
21. Kobayashi T, Suzuki K. A taurodeoxycholate-activated galactosylceramidase in the murine intestine. J Biol Chem 1981; 256(3): 1133-1137.
22. Merrill AH, Schmelz EM, Wang E, Schroeder JJ, Dillehay DL, Riley RT. Role of dietary sphingolipids and inhibitors of sphingolipid metabolism in cancer and other diseases. J Nutr 1995; 125(S6):1677S-1682S.
23. Schmelz EM, Crall KJ, Larocque R, Dillehay DL, Merrill AH. Uptake and metabolism of sphingolipids in isolated intestinal loops of mice. J Nutr 1994; 124: 702-712.
24. Garmy N, Taieb N, Yahi N, Fantini J. Apical uptake and transepithelial transport of sphingosine monomers through intact human intestinal epithelial cells: Physicochemical and molecular modeling studies. Arch Biochem Biophys 2005; 440(1): 91-100.
25. Vesper H, Schmelz EM, Nikolova-Karakashian MN, Dillehay DL, Lynch DV, Merrill AH. Sphingolipids in food and the emerging importance of sphingolipids to nutrition. J Nutr 1999; 129(7): 1239-1250.
26. Ahn EH, Schroeder JJ. Bioactive sphingolipids are constituents of soy and dairy products. J Food Sci 2002; 67(2): 522-524.
27. Souci SW, Fachmann W, Kraut H. Food composition and nutrition tables. 6th ed. Stuttgart; Boca Raton, New York, Washington D.C.: Medpharm Scientific Publishers; CRC Press, 2000.
28. Gutierrez E, Wang T, Fehr WR. Quantification of sphingolipids in soybeans. J Am Oil Chem Soc 2004; 81(8): 737-742.
29. Gremaud G, Schmid I, Sieber R. In: Eichholzer M, Camenzind-Frey E, Matzke A, Amadò R, Ballmer PE Eds, Fünfter Schweizerischer Emährungsbericht. Bern, Bundesamt für Gesundheit. 2005; 7-24.
30. Jensen RG, Newburg DS. In: Jensen RG Ed, Handbook of milk composition. San Diego CA, Academic Press Inc. 1995; 543-575.
31. Parodi PW. Cows' milk fat components as potential anticarcinogenic agents. J Nutr 1997; 127(6): 1055-1060.
32. Puente R, Garciapardo LA, Rueda R, Gil A, Hueso P. Seasonal variations in the concentration of gangliosides and sialic acids in milk from different mammalian species. Int Dairy J 1996; 6(3): 315-322.
33. Bitman J, Wood DL. Changes in milk fat phospholipids during lactation. J Dairy Sci 1990; 73: 1208-1216.
34. Nyberg L. Digestion and absorption of sphingomyelin from milk. 1998. Thesis/Dissertation. University Hospital of Lund, Sweden.
35. Avalli A, Contarini G. Determination of phospholipids in dairy products by SPE/HPLU/ELSD. J Chromatogr A 2005; 1071(1-2): 185-190.
36. Christie WW, Noble RC, Davies G. Phospholipids in milk and dairy products. J Soc Dairy Technol 1987; 40(1): 10-12.
37. Dillehay DL, Webb SK, Schmelz EM, Merrill AH. Dietary sphingomyelin inhibits 1,2-dimethylhydrazine-induced colon cancer in CF1 mice. J Nutr 1994; 124: 615-620.
38. Castegnaro M, Garren L, Galendo D, et al. Analytical method for the determination of sphinganine and sphingosine in serum as a potential biomarker for fumonism exposure. J Chromatogr B 1998; 720(1-2): 15-24.
39. Ribar S, Mesaric M, Sedic M. Sphingoid bases as possible diagnostic parameters. Croat Mod J 2003; 44(2): 165-170.
40. Solfrizzo, M, Avantaggiato G, Visconti A. Rapid method to determine sphinganine/sphingosine in human and animal urine as a biomarker for fumonisin exposure. J Chromatogr B 1997; 692(1): 87-93.
41. van der Westhuizen L, Brown NL, Marasas WFO, Swanevelder S, Shephard GS. Sphinganine/sphingosine ratio in plasma and urine as a possible biomarker for fumonisin exposure in humans in rural areas of Africa. Food Chem Toxicol 1999; 37(12): 1153-1158.
42. Abnet CC, Borkowf CB, Qiao YL, et al. A cross-sectional study of human serum sphingolipids, diet and physiologic parameters. J Nutr 2001; 131(10): 2748-2752.
43. Li ZQ, Basterr MJ, Hailemariam TK, et al. The effect of dietary sphingolipids on plasma sphingomyelin metabolism and atherosclerosis. Biochim Biophys Acta 2005; 1735(2): 130-134.
44. Imaizumi K, Tominaga A, Sato M, Sugano M. Effects of dietary sphingolipids on levels of serum and liver lipids in rats. Nutr Res 1992; 12(4-5): 543-548.
45. Park EJ, Suh K Ramanujam K, Steiner K, Begg D, Clandinin TT. Diet-induced changes in membrane gangliosides in rat intestinal inucosa, plasma and brain. J Pediatr Gastroenterol Nutr 2005; 40(4): 487-495.
46. Sprong RC, Hulstein MFE, van der Meer R. Bovine milk fat components inhibit food-borne pathogens. Int Dairy J 2002; 12(2-3): 209-215.
47. Koopman JS, Turkish VJ, Monto AS, Thompson FE, Isaacson RE. Milk fat and gastrointestinal illness. Am J Public Health 1984; 74: 1371-1373.
48. Sheu CW, Freese E. Lipopolysaccharide layer protection of Gram-negative bacteria against inhibition by long-chain fatty acids. J Bacteriol 1973; 115(3): 869-875.
49. Sprong RC, Hulstein MFE, van der Meer R. Bactericidal activities of milk lipids. Antimicrob Agents Chemother 2001; 45(4): 1298-1301.
50. Sprong RC, Hulstein MFE, van der Meer R. Bovine milk fat components inhibit food-borne pathogens. Int Dairy J 2002; 12(2-3): 209-215.
51. Possemiers S, Van Camp J, Bolca S, Verstraete W. Characterization of the bactericidal effect of dietary sphingosine and its activity under intestinal conditions. Int J Food Microbiol 2005; 105: 59-70.
52. Rueda R, Sabatel JL, Maldonaldo J, Molina-Font JA, Gil A. Addition of gangliosides to an adapted milk formula modifies levels of fecal Escherichia coli in preterm newborn infants. J Pediatr 1998; 133(1): 90-94.
53. Pan XL, Izumi T. Variation of the ganglioside compositions of human milk, cow's milk and infant formulas. Early Hum Dev 2000; 57(1): 25-31.
54. Rueda R, Maldonaldo J, Narbona E, Gil A. Neonatal dietary gangliosides. Early Hum Dev 1998; 53: S135-S147.
55. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998; 338(23):1641-1649.
56. Desai NN, Zhang H, Olivera A, Mattie ME, Spiegel S. Sphingosine-1-Pposphate, a metabolite of sphingosine increases phosphatidic-acid levels by phospholipase D activation. J Biol Chem 1992; 267(32): 23122-23128.
57. Garg SK, Volpe E, Palmieri G, et al. Sphingosine 1-phosphate induces antimicrobial activity both in vitro and in vivo. J Infect Dis 2004; 189(11): 2129-2138.
58. Kusner DJ, Hall CF, Schlesinger LS. Activation of phospbolipase D is tightly coupled to the phagocytosis of Mycobacterium tuberculosis or opsonized zymosan by human macrophages. J Exper Med 1996; 184(2): 585-595.
59. Giron-Calle J, Forman HJ. Phospholipase D and priming of the respiratory burst by H2O2 in NR8383 alveolar macrophages. Am J Respir Cell Mol Biol 2000; 23(6): 748-754.
60. Melendez A, Floto RA, Gillooly DJ, Harnett MM, Allen JM. Fc gamma RI coupling to phospholipase D initiates sphingosine kinase-mediated calcium mobilization and vesicular trafficking. J Biol Chem 1998; 273(16): 9393-9402.
61. Fairbairn IP, Stober CB, Kumararatne DS, Lammas DA. ATP-mediated killing of intracellular mycobacteria by macrophages is a P2X(7)-dependent process inducing bacterial death by phagosome-lysosome fusion. J Immunol 2001; 167(6): 3300-3307.
62. Pfeuffer M, Schrezenmeir J. Dietary sphingolipids: Metabolism and potential health implications. Kieler Milchw Forschungsber 2001; 53(1): 31-42.
63. Radin NS. Preventing the binding of pathogens to the host by controling sphingolipid metabolism. Microbes Infect 2006; 8: 938-945.
64. Fantini J, Hammache D, Delezay O, et al. Synthetic soluble analogs of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry. J Biol Chem 1997; 272(11): 7245-7252.
65. Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem 2000; 275(23): 17221-17224.
66. Garmy N, Taieb N, Yahi N, Fantini J. Interaction of cholesterol with sphingosine: physicochemical characterization and impact on intestinal absorption. J Lipid Res 2005; 46(1): 36-45.
67. Noh SY, Koo SI. Egg sphingomyelin lowers the lymphatic absorption of cholesterol and alpha-tocopherol in rats. J Nutr 2003; 133(11): 3571-3576.
68. Noh SK, Koo SI. Milk sphingomyelin is more effective than egg sphingomyelin in inhibiting intestinal absorption of cholesterol and fat in rats. J Nutr 2004; 134(10): 2611-2616.
69. Eckhardt ERM, Wang DQH, Donovan JM, Carey MC. Dietary sphingomyelin suppresses intestinal cholesterol absorption by decreasing thermodynamic activity of cholesterol monomers. Gastroenterology 2002; 122(4): 948-956.
70. Nyberg L, Duan RD, Nilsson A. A mutual inhibitory effect on absorption of sphingomyelin and cholesterol. J Nutr Biochem 2000; 11(5): 244-249.
71. Jiang YZ, Noh SK, Koo SI. Egg phosphatidylcholine decreases the lymphatic absorption of cholesterol in rats. J Nutr 2001; 131(9): 2358-2363.
72. Hopkins PN, Williams RR. A survey of 246 suggested coronary risk factors. Atherosclerosis 1981; 40: 1-52.
73. Deguchi H, Fernandez JA, Pabinger I, Heit JA, Griffin JH. Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood 2001; 97(7): 1907-1914.
74. Jeong TS, Schissel SL, Tabas I, Pownall HJ, Tall AR, Jiang XC. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest 1998; 101 (4): 905-912.
75. Jiang XC, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M, et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000; 20(12): 2614-2618.
76. Portman OW, Alexande M. Metabolism of sphingolipids by normal and atherosclerotic aorta of squirrel monkeys. J Lipid Res 1970; 11(1): 23-30.
77. Marathe S, Schissel SL, Yellin MJ, et al. Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase - Implication for early atherogenesis and ceramide-mediated cell signaling. J Biol Chem 1998; 273(7): 4081-4088.
78. Schissel SL, Tweedie Hardman J, Rapp JH, Graham G, Williams KJ, Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein - Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 1996; 98(6): 1455-1464.
79. Schissel SL, Jiang XC, Tweedie-Hardman J, Jeong TS, Camejo EH, Najib J, et al. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH - Implications for atherosclerotic lesion development. J Biol Chem 1998; 273(5): 2738-2746.
80. Wong ML, Xie BX, Beatini N, Phu P, Marathe S, Johns A, et al. Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: A possible link between inflammatory cytokines and atherogenesis. Proc Natl Acad Sci USA 2000; 97(15): 8681-8686.
81. Xia P, Vadas MA, Rye KA, Barter PJ, Gamble JR. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway - A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 1999; 274(46): 33143-33147.
82. Xia P, Wang LJ, Gamble JR, Vadas MA. Activation of sphingosine kinase by tumor necrosis factor-alpha inhibits apoptosis in human endothelial cells. J Biol Chem 1999; 274(48): 34499-34505.
83. Augé N, Andrieu N, Negresalvayre A, Thiers JC, Levade T, Salvayre R. The sphingomyelin-ceramide signaling pathway is involved in oxidized low density lipoprotein-induced cell proliferation. J Biol Chem 1996; 271(32): 19251-19255.
84. Deigner BP, Claus R, Bonaterra GA, et al. Ceramide induces aSMase expression: implications for oxLDL-induced apoptosis. FASEB J 2001; 15(3): 807-814.
85. Mukhin DN, Prokazova NV, Bergelson LD, Orekhov AN. Ganglioside content and composition of cells from normal and atherosclerotic human aorta. Atherosclerosis 1989; 78(1): 39-45.
86. Mukhin DN, Chao FF, Kruth HS. Glycosphingolipid accumulation in the aortic wall is another feature of human atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15(10): 1607-1615.
87. Rodriguez JL, Ghiselli GC, Torreggiani D, Sirtori CR. Very low-density lipoproteins in normal and cholesterol-fed rabbits - Lipid and protem composition and metabolism .1. Chemical composition of very low-density lipoproteins in rabbits. Atherosclerosis 1976; 23(1): 73-83.
88. Kobayashi T, Shimizugawa T, Osakabe T, Watanabe S, Okuyama H. A long-term feeding of sphingolipids affected the levels of plasma cholesterol and hepatic triacylglycerol but not tissue phospholipids and sphingolipids. Nutr Res 1997; 17(1): 111-114.
89. Glinghammar B, Venturi K Rowland IR, Rafter JJ. Shift from a dairy product-rich to a dairy product-free diet: influence on cytotoxicity and genotoxicity of fecal water - potential risk factors for colon cancer. Am J Clin Nutr 1997; 66(5): 1277-1282.
90. Holt PR, Atillasoy EO, Gilman J, el al. Modulation of abnormal colonic epithelial cell proliferation and differentiation by low-fat dairy foods - A randomized controlled trial. JAMA 1998; 280(12): 1074-1079.
91. Schmelz EM, Dillehay DL, Webb SK, Reiter A, Adams J, Merrill AH. Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis. Cancer Res 1996; 56: 4936-4941.
92. Schmelz EM, Sullards MC, Dillehay DL, Merrill AH. Colonic cell proliferation and aberrant crypt foci formation are inhibited by dairy glycosphingolipids in 1,2-dimethylhydrazine-treated CF1 mice. J Nutr 2000; 130(3): 522-527.
93. Zeisel SH, Char D, Sheard NF. Choline, phosphatidylcholine and sphingomyelin in human and bovine-milk and infant formulas. J Nutr 1986; 116(1): 50-58.
94. Schmelz EM, Dombrink-Kurtzman MA, Roberts PC, Kozutsumi Y, Kawasaki T, Merrill AH. Induction of apoptosis by fumonisin B1 in HT29 cells is mediated by the accumulation of endogenous free sphingoid bases. Toxicol Appl Pharmacol 1998; 148: 252-260.
95. Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 1994; 269(5): 3125-3128.
96. Berra B, Colombo I, Sottocomola E, Giacosa A. Dietary sphingolipids in colorectal cancer prevention. Eur J Cancer Prev 2002; 11(2): 193-197.
97. Tsyupko AN, Dudnik LB, Evstigneeva RP, Alessenko AV. Effects of reduced and oxidized glutathione on sphingomyelinase activity and contents of sphingomyelin and lipid peroxidation products in murine liver. Biochemistry (Mosc) 2001; 66(9): 1028-1034.
98. Colombaioni L, Garcia-Gil M. Sphingolipid metabolites in neural signalling and function. Brain Res Rev 2004; 46(3): 328-355.
99. MacLennan AJ, Carney PR, Zhu WJ, Chaves AH, Garcia J, Grimes JR, et al. An essential role for the H218/AGR16/Edg-5/LPB2 sphingosine 1-phosphate receptor in neuronal excitability. Eur J Neurosci 2001; 14(2): 203-209.
100. Oshida K, Shimizu T, Takase M, Tamura Y, Shimizu T, Yamashiro Y. Effects of dietary sphingomyelin on central nervous system myelination in developing rats. Pediatr Res 2003; 53(4): 589-593.
101. Wang B, Brand-Miller J. The role and potential of sialic acid in human nutrition. Eur J Clin Nutr 2003; 57(11): 1351-1369.
102. Svennerholm L. In: Ouchterlony, Holmgrem Eds, Structure and biology of cell membrane gangliosides. Cholera and related diarrheas: Molecular aspects of a global health problem. Basel, New York, S. Karger. 1980.
103. Schauer R. Sialic acids, chemistry, metabolism, and function. Wien, New York, Springer Verlag. 1982.
104. Fergusson DM, Beautrais AL, Silva PA. Breast-feeding and cognitive-development in the 1St 7 years of life. Soc Sci Med 1982; 16(19): 1705-1708.
105. Lucas A, Morley R, Cole TJ, Lister G, Leesonpayne C. Breast-milk and subsequent intelligence quotient in children born preterm. Lancet 1992; 339: 261-264.
106. Lucas A, Morley R, Cole TJ. Randomised trial of early diet in preterm babies and later intelligence quotient. BMJ 1998; 317: 1481-1487.
107. Rodgers B. Feeding in infancy and later ability and attainment - Longitudinal-study. Dev Med Child Neurol 1978; 20(4): 421-426.
108. Dewey KG, Peerson JM, Brown KH, et al. Growth of breast-fed infants deviates from current reference data - A pooled analysis of US, Canadian, and European data sets. Pediatrics 1995; 96(3): 495-503.
109. Mortensen EL, Michaelsen KF, Sanders SA, Reinisch JM. The association between duration of breastfeeding and adult intelligence. JAMA 2002; 287(18): 2365-2371.
110. Cutler RG, Kelly J, Storie K, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 2004; 101 (7): 2070-2075.
111. Svennerholm L, Brane G, Karlsson I, Lekman A, Ramstrom I, Wikkelso C. Alzheimer disease - Effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme. Dement Geriatr Cogn Disord 2002; 14(3): 128-136.
112. Svennerholm L. Gangliosides - A new therapeutic agent against stroke and Alzheimers-disease. Life Sci 1994; 55(25-26): 2125-2134.
113. Molander-Melin M, Blennow K, Bogdanovic N, Dellheden B, Mansson JE, Fredman P. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem 2005; 92(1): 171-182.